Performance and Usefulness of a Novel Automated Immunoassay HISCL SARS-CoV-2 Antigen Assay Kit for the Diagnosis of COVID-19

Kaori Saito
  Juntendo University: Juntendo Daigaku

Tomohiko Ai
  The Ohio State University College of Medicine
  https://orcid.org/0000-0003-0376-0227

Akinori Kawai
  Sysmex Corp: Sysmex Kabushiki Kaisha

Jun Matsui
  Sysmex Corp: Sysmex Kabushiki Kaisha

Yoshiyuki Fukushima
  Sysmex Corp: Sysmex Kabushiki Kaisha

Norihiro Kikukawa
  Sysmex Corp: Sysmex Kabushiki Kaisha

Takuya Kyoutou
  Sysmex Corp: Sysmex Kabushiki Kaisha

Masayoshi Chonan
  Juntendo University: Juntendo Daigaku

Takeaki Kawakami
  Sysmex Corp: Sysmex Kabushiki Kaisha

Yoshie Hosaka
  Juntendo University: Juntendo Daigaku

Shigeki Misawa
  Juntendo University: Juntendo Daigaku

Haruhi Takagi
  Juntendo University: Juntendo Daigaku

Yasushi Matsushita
  Juntendo University: Juntendo Daigaku

Makoto Hiki
  Juntendo University: Juntendo Daigaku

Atsushi Okuzawa
  Juntendo University: Juntendo Daigaku

Satoshi Hori
Abstract

**Background:** The aim of this study was to evaluate the clinical performance of a newly developed automated immunoassay HISCL SARS-CoV-2 Antigen assay kit designed to detect the nucleocapsid (N) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

**Methods:** The HISCL SARS-CoV-2 Antigen assay kit is composed of automated chemiluminescence detection systems. Western blot analysis confirmed that anti-SARS-CoV antibodies detected SARS-CoV-2 N proteins. The best cut-off index (COI) was determined using human serum samples obtained from coronavirus disease-2019 (COVID-19) patients and patients without COVID-19. To test the clinical performance, 115 samples obtained from 46 patients with COVID-19 and 69 individuals who tested negative for COVID-19 using reverse transcription quantitative polymerase chain reaction (RT-qPCR) were used.

**Results:** The HISCL antigen assay kit showed a sensitivity of 95.4 % in the samples with copy numbers of >100, and a sensitivity of 16.6 % in the samples with copy numbers of <99. The kit did not cross-react with other human corona viruses causing seasonal common cold (HCoV 229E, OC43, NL63, and HKU1) and influenza (H1N1, H3N2, and B), and none of the 69 individuals with negative RT-qPCR results were diagnosed as positive. Importantly, 81.8 % of the samples with low virus load (<50 copy numbers) were diagnosed as negative. Thus, use of the HISCL antigen assay kit may reduce overdiagnosis compared with RT-qPCR tests.

**Conclusion:** The rapid and high-throughput HISCL SARS-CoV-2 Antigen assay kit developed in this study can be used as a suitable screening test for infectious COVID-19, and may play a role in controlling the pandemic.

**Background**

The coronavirus disease-2019 (COVID-19) pandemic originating from Wuhan, China has caused chaos and health and economic crises across the world [1–7] despite numbers of infection and death cases are far fewer than those of the 1918 influenza pandemic [8]. The World Health Organization declared COVID-19 a pandemic in March 2020.

Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is contagious in humans, it is important to determine the infection status of individuals accurately [9]. During the early phase of the pandemic, a reverse transcriptase quantitative-polymerase chain reaction (RT-qPCR) based test was considered a gold standard. However, a meta-analysis of 51 studies reported that the overall sensitivity of PCR tests was 89.1% and the specificity was 98.9%, even though the true definition of COVID-19 remains ambiguous [10]. In addition, results can vary because the accuracy of PCR tests can be significantly affected by various factors, such as primer designs and sample collection techniques, reagents, and laboratory equipment. Furthermore, patients can be tested positive for COVID-19 by PCR tests during post-infectious periods [11] as the cut-off can be changed by altering the cycle threshold (Ct) values. For
example, low, clinically insignificant amounts of viral RNAs can still be detected when the Ct is set to
more than 35, suggesting a positive result. This indicates that the relationships between Ct values and
infectious status is debatable [12–14] since non-infectious COVID-19 individuals can be labeled as
positive due to overdiagnosis by RT-qPCR tests [15–17]. This issue raises serious concerns, not only in
terms of medical decisions but also with regard to the global economy and the protection of human
rights [18–21].

Recently, SARS-CoV-2 antigen detection assays were developed as potential alternative tests to RT-qPCR
to identify infectious patients, as stated by the U.S. Food and Drug Administration
(https://www.fda.gov/consumers/consumer-updates/coronavirus-disease-2019-testing-basics). In the
eyear phase of the COVID-19 pandemic, Ag Respi-Strip, an immunochromatographic assay, was
developed (Coris BioConcept, Gembloux, Belgium) in which monoclonal antibodies against the
nucleocapsid (N) protein of SARS-CoV were used. The LHUB-ULB SARS-CoV-2 working diagnostic group
reported that the COVID-19 Ag Respi-Strip assay showed overall sensitivity and specificity of 57.6% and
99.5%, respectively [22]. In June 2020, LUMIPULSE G1200 using a chemiluminescence enzyme
immunoassay became available (Fujirebio, Tokyo, Japan), and its overall sensitivity and specificity in
Japanese patients was 55.2% and 99.6%, respectively [23].

We developed an automated antigen detection system, which we termed as the HISCL SARS-CoV-2
Antigen assay kit that can detect the N protein of SARS-CoV-2 using enzyme-linked immunosorbent
assay (ELISA). This automated test can process 200 samples per hour, making it suitable for mass
screening. In this study, we examined the feasibility and accuracy of the HISCL SARS-CoV-2 Antigen
assay kit for screening COVID-19 patients in Japan.

**Methods**

**Patient samples**

The research related to human use has been complied with all the relevant national regulations,
institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by
the authors’ institutional review board at Juntendo University Hospital, Tokyo, Japan (IRB #20-036) and
Kobe City Medical Center General Hospital, Hyogo, Japan (IRB #zn200615). This study used an opt-out
consent method. Therefore, written informed consent was not required.

Classification of disease severity was determined according to the Clinical Spectrum of SARS-CoV-2
Infection (https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/). To determine
the relationship between photo counts and viral loads, a total of 84 nasopharyngeal swabs were collected
from 17 patients at Kobe City Medical Center General Hospital and 67 commercially available samples
(Cantor Bioconnect, Santee, CA, USA; validation dataset). For clinical performance analysis, a total of 115
nasopharyngeal swabs were collected from 115 patients at Juntendo University Hospital (test dataset).

**SARS-CoV-2 RT-qPCR**
Viral RNAs were extracted using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). RT-qPCR was performed following the protocol developed by the National Institute of Infectious Diseases of Japan. The primer/probe set (N2) was designed based on the N sequence of SARS-CoV-2 RNA (NC_045512.2) [24]. The primer/probe sequences were as following: forward primer (5’-AAATTTTGGGGACCAGGAAC-3’), reverse primer (5’-TGGCAGCTGTGTAGGTCAAC-3’), and TaqMan probe (5’-FAM-ATGTGCATGGA-BHQ-3’). The expected amplicon size was 158 bp. QuantiTect Probe RT-PCR Kit (Qiagen, Germantown, MD, USA) and Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA) were used. The Ct values were assessed using the protocol developed by the National Institute of Infectious Diseases (version 2.9.1) [24]. The association between absolute viral copy numbers (viral loads) and Ct values was determined using SARS-CoV-2 Positive Control RNA (JP-NN2-PC, Nihon Gene Research Laboratories, Miyagi, Japan).

**Recombinant antigen production**

For antigen cross-reactivity tests, nucleocapsid antigens derived from the other coronaviruses and influenza viruses were prepared. The recombinant nucleocapsid proteins were produced based on the following sequences: SARS-CoV (YP_009825061), Middle East respiratory syndrome-related coronavirus (MERS-CoV; YP_009047211), human coronavirus HKU1 HCoV-HKU1 (YP_173242), HCoV-OC43 (YP_009555245), HCoV-NL63 (YP_003771), and HCoV-229E (NP_073556). Each recombinant protein was prepared according to previously described methods [25].

**Western blot**

The detection of SARS-CoV-2 antigens by SARS-CoV antibodies was confirmed via western blot analysis using the previously produced anti-N capsid SARS-CoV antibodies [25]. Histidine (His)-tagged SARS-CoV-2 N proteins (10 ng) were loaded on NEXT Page II gel (5–20% gradient; Gellex, Tokyo, Japan) and electrophoresis was performed using iBind Western Device (Thermo Fisher Scientific). Two lots each of anti-SARS-CoV antibodies (0.5 μg/mL) and horseradish peroxidase (HRP)-conjugated anti-His antibodies (Penta-His Antibody; Cat. No. 34660, Qiagen) were used as primary antibodies. Anti-IgG antibodies (Medical & Biological Laboratories, Nagoya, Japan) were used as the secondary antibodies. Immobilon Western HRP substrate (Millipore, Burlington, MA, USA) was used for chemiluminescent detection.

**HISCL SARS-CoV-2 Antigen assay kit**

Previously produced monoclonal antibodies against the SARS-CoV N proteins [25] were used to probe the SARS-CoV-2 N proteins (ACROBiosystems, Newark, DE, USA). The HISCL SARS-CoV-2 Antigen assay kit is a chemiluminescent enzyme immunoassay that uses a HISCL automatic immunoassay analyzer (Sysmex, Kobe, Japan).

**Figure 1** presents a schematic illustration of the procedure: (1) the samples were incubated with biotinylated SARS-CoV-2 antibodies at 42 °C for 3 min; (2) the mixtures were incubated with streptavidin-bonded magnetic particles at 42 °C for 2 min; (3) after protein separation and washing, alkaline
phosphatase (ALP)-bound SARS-CoV-2 antibodies were added and the mixtures were incubated at 42 °C for 3 min; (4) after magnetic separation and washing again, the chemiluminescent substrates were added and the mixtures were incubated at 42°C for 5.5 min; and (5) chemiluminescence signals (CDP-Star, C0712, Sigma-Aldrich, St. Louis, MO, USA) were measured using the photo counter of HISCL-800 (Sysmex, Kobe, Japan). The level of SARS-CoV-2 Ag was indicated as cut-off index (COI), calculated by the difference in the luminescence intensities in the buffers with and without the SARS-CoV-2 antigens.

**Human sample collection**

Human samples were obtained using nasopharyngeal cotton swabs following the standard method [26]. The swabs were immersed in 0.5 mL phosphate-buffered saline or viral transfer medium (Lampire Biological Laboratories, Pipersville, PA, USA). The suspensions were frozen at -80 °C until antigen tests were performed. Highly viscous samples were centrifuged (2,000 × g for 5 minutes), and the supernatants were used for subsequent analyses.

**Reproducibility**

Within-run and between-run reproducibility were determined by running the buffers with and without SARS-CoV-2 antigens. The recombinant human antigen for SARS-CoV-2 was purchased from ACRO Biosystems (Beijing, China). To test reproducibility, buffers containing SARS-CoV-2 antigens (positive control) and those without antigens (negative control) were prepared. To test between-run reproducibility, both negative and positive controls were tested twice per day each for five consecutive days.

**Cross-reaction**

Cross-reactions were checked using measuring buffers containing various recombinant viral antigens: human SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, influenza virus H1N1, influenza virus H3N2, and influenza virus B. Inactivated influenza viruses were purchased from Advanced Biotechnologies (Eldersburg, MD, USA). The antigens of SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 were prepared according to a previous established protocol [25]. HISCL SARS-CoV-2 Antigen assays were carried out following the manufacturer’s instructions.

**Statistical analyses**

Statistical analyses were performed in Excel (Microsoft, Redmond, WA, USA). Receiver operating characteristic (ROC) curve analyses were conducted using GraphPad Prism (GraphPad Software, San Diego, USA) to evaluate the assay performance and visualize the curves. The areas under the ROC curves (AUCs), sensitivity, and specificity were calculated.

**Results**

**Western blot**
We first verified whether the previously produced anti-SARS-CoV antibodies detected SARS-CoV-2. **Figure 2** shows that the anti-SARS-CoV antibodies (lane 1, antibody 2–3; lane 2, antibody 2–13) and anti-His antibody (lane 3) detected the SARS-CoV-2 antigens but not negative control (lane 4).

**Determination of the association between Ct values and viral loads**

To determine the relationship between Ct values obtained by RT-qPCR and viral copy numbers, SARS-CoV-2 Positive Control RNA (1×10^5 copies/µL; JP-NN2-PC, Nihon Gene Research Laboratories) was sequentially diluted (50 to 5,000 copies/sample) and subjected to RT-qPCR. **Figure 3** shows the standard curve of Ct values as a function of copy numbers using four RNA samples for each copy number. The plots were fitted with linear regression, yielding the slope of -3.43 and the intercept of 50.1 ($r^2 = 0.999$).

**Reproducibility**

To check the reproducibility of the HISCL SARS-CoV-2 Antigen assay kit, we measured one sample containing recombinant SARS-CoV-2 antigens (positive control) and one sample containing only buffers (negative control). The tests were repeated ten times for each sample and all experiments were conducted in triplicate. **Table 1** shows the COI values for both samples. The negative control showed 100% agreement with COI of zero, and the positive control showed the average COI of 27.7 to 28.8 with coefficient of variation (CV) percentage of 1.3–2.5.

**Table 1. Within-run reproducibility**
| Control panels | COI   |
|----------------|-------|
| Negative control |       |
| 1   | 0 0 0 0 |
| 2   | 0 0 0 0 |
| 3   | 0 0 0 0 |
| 4   | 0 0 0 0 |
| 5   | 0 0 0 0 |
| 6   | 0 0 0 0 |
| 7   | 0 0 0 0 |
| 8   | 0 0 0 0 |
| 9   | 0 0 0 0 |
| 10  | 0 0 0 0 |
| Positive control |       |
| 1   | 28.4 27.9 29 |
| 2   | 29 27.3 29 |
| 3   | 29 26.3 27.3 |
| 4   | 28.4 27.9 27.9 |
| 5   | 29 27.3 27.9 |
| 6   | 28.4 27.9 27.9 |
| 7   | 28.4 27.9 28.4 |
| 8   | 29 28.4 28.4 |
| 9   | 27.9 29 27.9 |
| 10  | 29 27.3 27.9 |
| Average | 28.7 27.7 28.2 |
| SD   | 0.4 0.7 0.5 |
| CV (%) | 1.3 2.5 1.8 |
To check between-run reproducibility, we measured the negative and positive control samples twice daily for 5 days. Table 2 shows that the COI of negative and positive controls showed consistent values (CV % <10).

**Table 2. Between-run reproducibility.**

| Negative control | COI | Run1 | Run2 | Mean | Run1 | Run2 | Mean |
|------------------|-----|------|------|------|------|------|------|
| Day1             | 0   | 0    | 0    | 0    | 0    | 0    | 0    |
| Day2             | 0.1 | 0.1  | 0.1  | 0    | 0.1  | 0    | 0    |
| Day3             | 0   | 0    | 0    | 0    | 0    | 0    | 0    |
| Day4             | 0   | 0    | 0    | 0    | 0    | 0    | 0    |
| Day5             | 0   | 0    | 0    | 0    | 0    | 0    | 0    |

| Positive control | COI | Run1 | Run2 | Mean | Run1 | Run2 | Mean |
|------------------|-----|------|------|------|------|------|------|
| Day1             | 26.8| 27.3 | 27   | 26.7 | 27   | 26.8 |
| Day2             | 27.5| 28.1 | 27.8 | 28   | 27.2 | 27.6 |
| Day3             | 28.4| 28.5 | 28.4 | 29   | 27.7 | 28.3 |
| Day4             | 28.2| 28   | 28.1 | 28.6 | 28.4 | 28.5 |
| Day5             | 30.7| 30.6 | 30.6 | 30.8 | 29.8 | 30.3 |

Average: 28.4, Ave: 28.3
SD: 1.3, SD: 1.3
CV (%): 4.7, CV (%): 4.6

COI: cut-off index; SD: standard deviation; CV: coefficient of variation.
Cross-reaction

Table 3 shows the COI measurements using samples containing various types of viruses. The COI showed high values for SARS at a concentration of 0.25 ng/mL and positive values for MERS-CoV at a low concentration. In contrast, the COI values stayed in the negative range for other coronaviruses and influenza viruses, indicating that the HISCL SARS-CoV-2 Antigen assay kit does not react with seasonal common cold and flu viruses.

### Table 3. Cut-off index (COI) values in negative controls.

| Panels       | Concentration (ng/mL) |
|--------------|-----------------------|
|              | 0         | 0.25 | 0.5  | 0.75 | 1     | 25    | 50    | 75    | 100   |
| MERS-CoV     | 0         | 1.1  | 2.3  | 3.3  | 4.6   | 11.9  | 23.6  | 34.3  | 46.2  |
| HCoV-229E    | 0         | -    | -    | -    | -     | 0     | 0     | 0     | 0     |
| HCoV-OC43    | 0         | -    | -    | -    | -     | 0     | 0.1   | 0.2   | 0.2   |
| HCoV-NL63    | 0         | -    | -    | -    | -     | 0     | 0     | 0     | 0.1   |
| HCoV-HKU1    | 0         | -    | -    | -    | -     | 0     | 0.1   | 0     | 0.1   |
| SARS-CoV     | 0         | 26   | 53   | 75.2 | 109.8 | 2938  | 5727.1| 8127.1| 10682.1|
| H1N1         | 0         | -    | -    | -    | -     | 0.1   | 0     | 0     | 0     |
| H3N2         | 0         | -    | -    | -    | -     | 0     | 0     | 0     | 0     |
| B            | 0         | -    | -    | -    | -     | 0     | 0     | 0     | 0     |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; MERS-CoV: Middle East respiratory syndrome-related coronavirus; HCoV-229E: human coronavirus 229E.

### Determination of the cut-off value

To optimize the cut-off Ag level for accurate diagnoses, we used 30 RT-qPCR positive and 54 negative samples. Chemiluminescence counts were measured by HISCL SARS-CoV-2 Antigen assay kit using these samples and recombinant SARS-CoV-2 proteins (0, 20, and 100 pg/mL). Viral loads (copy numbers) were calculated based upon the relationships between Ct values and RNA content (Additional file Table 1). Sensitivity and specificity were calculated at different cut-off values depending upon the RT-qPCR results (i.e., copy number 0 as negative). When the cut-off for the Ag level was set to 3.65 pg/mL, the sensitivity and specificity reached their highest levels (Table 4). Thus, chemiluminescence count using 3.65 pg/mL Ag was set to a COI value of 1.0 in the HISCL SARS-CoV-2 Antigen assay kit. Figure 4 shows that the ROC analysis yielded an AUC value of 0.8988 ± 0.0464 (95% confidence interval, 0.808–0.990, p<0.0001).
Table 4. Sensitivity and specificity according to various cut-off values.

| Cut-off value | Sensitivity (%) | Specificity (%) |
|---------------|----------------|-----------------|
| SARS-CoV-2 Ag (pg/mL) | | |
| 1.65          | 86.7            | 81.5            |
| 2.6           | 80              | 90.7            |
| 3.65          | 80              | 98.2            |
| 4.45          | 73.3            | 98.2            |
| 6             | 63.3            | 98.2            |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

Table 5 summarizes the concordance between the two tests in three viral load ranges using the cut-off value in validation samples.

Table 5. Relationship between the SARS-CoV-2 viral loads and COI in the assay kit using commercial samples.

| RT-qPCR | SARS-CoV-2 Ag test | Total |
|---------|-------------------|-------|
| (copies/test) | Positive | Negative |
| 1-50     | 1      | 4      | 5     |
| 51-99    | 4      | 1      | 5     |
| >100     | 19     | 1      | 20    |

COI, cut-off-index; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-qPCR, reverse transcription quantitative polymerase chain reaction; Ag, antigen

Clinical performance

To examine the clinical performance, a total of 115 nasopharyngeal swab samples obtained from 115 patients at Juntendo University Hospital were subjected to the RT-qPCR and the HISCL SARS-CoV-2 Antigen assay kit. The RT-PCR showed 46 positive and 69 negative results. The SARS-CoV-2 viral loads...
determined by the RT-qPCR and the antigen levels detected by HISCL SARS-CoV-2 Antigen assay kit for each patient are listed in Additional file Table 2. Figure 5 shows a dot plot of the positive COI values (>1.0) against the viral copy numbers. The positive COI values obtained within 10 days from the onset for mild cases (n = 16) and moderate–critical cases (n = 5) had a mean [interquartile range] of 330.5 [27.6; 3849.3] and 233.9 [5.5; 1241.3], respectively (p = 0.860). Table 6 summarizes the concordance between the two tests in the two viral load ranges. The antigen tests showed 95.4% positive results in samples whose viral copy numbers were higher than 100. In samples whose copy numbers were lower than 99, the antigen test showed negative results in 20 samples and positive results in four samples.

Table 6. Relationship between the SARS-CoV-2 viral loads and COI by the HISCL SARS-CoV-2 Antigen assay kit.

| RT-qPCR (copies/test) | SARS-CoV-2 Ag test | Total |
|-----------------------|------------------|-------|
|                       | Positive | Negative |
| 1–99                  | 4        | 20      | 24    |
| >100                  | 21       | 1       | 22    |

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-qPCR, reverse transcription quantitative polymerase chain reaction; Ag, antigen.

Discussion

In this study, we evaluated the performance of HISCL SARS-CoV-2 Antigen assay kit using chemiluminescent enzyme immunoassay in comparison with RT-qPCR test results. This test was approved by the Pharmaceuticals and Medical Device Agency of Japan in November 2020, and it is currently commercially available (Sysmex, Kobe, Japan). This automated test can process 200 samples per hour, and the run time is only 17 minutes. Therefore, it can be used as a high-throughput screening test.

Since the early phase of this pandemic, RT-qPCR tests have been used for diagnoses, epidemiological studies, and political decision making [27–29]. Severe cases with high infectivity usually show high viral loads (i.e., low Ct values) and vice versa [30]. However, the interpretation of positive results needs extra caution because Ct values can vary due to differences in PCR conditions [31]. Importantly, infectivity cannot be determined solely based on RT-qPCR results [11].

To examine the correlation between RT-qPCR and our new antigen detection assay, we used SARS-CoV-2 RNAs as a standard. Our assay showed 95.4% concordance in the samples with a COI of >100, and the concordance decreased to 16.7% in samples with a COI of <99. LUMIPULSE assay (Fujirebio, Tokyo, Japan) showed 100% concordance in samples with >100 copies [23]. This may be due to the small
sample numbers used in both the studies, but it may also be attributed to the difference in the standard RNA (AccuPlex SARS-CoV-2 Reference Material Kit; SeraCare, Milford, MA, USA) and RT-qPCR methods (QuantiTect Probe RT-PCR Kit and Applied Biosystems 7500 Fast Real-Time PCR System versus StepOnePlus Real-Time PCR System).

Nonetheless, this difference should not be problematic in clinical practice since the viral loads in infectious patients were much higher than copy numbers of 100. For example, Yu et al. reported that copy number of SARS-CoV-2 in sputum samples in early-phase infection was 46.800 ± 17.272, and 1.252 ± 1.027 in the recovery phase [32]. Wölfel et al. reported that the pharyngeal virus shedding was high during the first week of symptoms, with a peak at $7.11 \times 10^8$ RNA copies per throat swab on day 4 [33]. Indeed, the viral loads (copy numbers) in our study were much lower than those in the previously reported cases, and mild cases showed similar COIs compared to moderate–critical cases (Additional file Table 2).

There were a few limitations of this study: (1) this study was performed only in Japan with a relatively small number of patients; (2) we could not test the assay for mutated pathogens that might not be bound by our antibody; (3) cross-reactivity with unknown pathogens could not be excluded. However, diagnoses of COVID-19 may not benefit clinical practice since no proven remedies are available to date; and (4) we could not examine chronological changes of the antigen test results.

**Conclusions**

In conclusion, considering the current chaotic situation across the world due to COVID-19, which is in part caused by detecting non-infectious patients with extremely low viral load as positive cases by RT-qPCR, our antigen detection assay may be more suitable than RT-qPCR for mass screening as it would help to moderate COVID-19 overdiagnoses. Further validation of the kit with a larger number of samples and SARS-CoV-2 variants is warranted.

**Abbreviations**

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; N: nucleocapsid; RT-qPCR: reverse transcription quantitative polymerase chain reaction; COI: cut-off index; CV: coefficient of variation; COVID-19: coronavirus disease-2019; Ag: antigen; Ct: cycle threshold; His: histidine; HRP: horseradish peroxidase; ROC: receiver operating characteristic; AUC: areas under the ROC curves; MERS-CoV: Middle East respiratory syndrome-related coronavirus; HCoV: human coronavirus.

**Declarations**

**Ethical approval:** Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013) and has been approved by the Institutional Review Board of Juntendo University Hospital, Tokyo, Japan (IRB #20-036) and Kobe City Medical Center General Hospital, Hyogo, Japan (IRB #zn200615).
Informed consent: Informed consent was waived for this study.

Data availability: The datasets supporting the conclusions of this article is(are) included within the article (and its additional files).

Competing interests:

Sysmex Corporation provided reagents for HISCL SARS-CoV-2 Antigen assay kit measurements free of charge. Akinori Kawai, Jun Matsui, Yoshiyuki Fukushima, Norihiro Kikukawa and Takuya Kyoutou are employees of Sysmex Corporation. This study was performed following strict adherence to academic standards.

Research funding: None

Author contributions:

TA and YT designed the study and wrote the paper. KS, AK, JM, YF, NK, TK, MC, TK and YH performed experiments. HT, YM and MH contributed to sample collection. SM, AO, SH, TN and TM contributed to data interpretation. KT supervised the study.

All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Acknowledgements

The authors are grateful to the participants of this study. The authors would also like to thank Dr Keisuke Tomii, Dr Atsushi Nakagawa, and Masaaki Eto at Kobe City Medical Center General Hospital for providing patient samples, and Koji Tsuchiya and Maiko Yuri for their technical support. Finally, we thank all our medical staff who conducted their duties diligently during the pandemic.

References

1. Zdravkovic M, Berger-Estilita J, Zdravkovic B, Berger D. Scientific quality of COVID-19 and SARS CoV-2 publications in the highest impact medical journals during the early phase of the pandemic: A case control study. PLoS One. 2020;15:e0241826.

2. Fleming N. Coronavirus misinformation, and how scientists can help to fight it. Nature. 2020;583:155–6.

3. Paterlini M. ‘Closing borders is ridiculous’: the epidemiologist behind Sweden's controversial coronavirus strategy. Nature. 2020;580:574.

4. Greene CM, Murphy G. Individual differences in susceptibility to false memories for COVID-19 fake news. Cogn Res Princ Implic. 2020;5:63.
5. Kenworthy N, Koon A, Mendenhall E. On symbols and scripts: The politics of the American COVID-19 response. Glob Public Health 2021:1–15.

6. Tokuda Y, Sakihama T, Aoki M, Taniguchi K, Deshpande GA, Suzuki S, et al. Authors’ reply: Independent investigation may be more reliable in the event with political nature. J Gen Fam Med. 2021;22:115.

7. Clarke EJR, Klas A, Dyos E. The role of ideological attitudes in responses to COVID-19 threat and government restrictions in Australia. Pers Individ Dif. 2021;175:110734.

8. Taubenberger JK, Kash JC, Morens DM. The 1918 influenza pandemic: 100 years of questions answered and unanswered. Sci Transl Med 2019;11.

9. Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020;13:1601–10.

10. Mustafa Hellou M, Gorska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. Clin Microbiol Infect 2020.

11. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. N Engl J Med. 2020;383:e120.

12. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill 2020;25.

13. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity. When Is It Safe to Discontinue Isolation? Clin Infect Dis; 2020.

14. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39:1059–61.

15. Roy S. Physicians’ Dilemma of False-Positive RT-PCR for COVID-19: a Case Report. SN Compr Clin Med 2021:1–4.

16. Ndwandwe D, Mathebula L, Adetokunboh O, Kamadjeu R, Wiysonge CS. Cochrane corner: universal screening for SARS-CoV-2 infection. Pan Afr Med J. 2020;37:48.

17. van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J Clin Virol. 2020;128:104412.

18. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020;8:1167–8.

19. Piltch-Loeb R, Jeong KY, Lin KW, Kraemer J, Stoto MA. Interpreting COVID-19 Test Results in Clinical Settings: It Depends! J Am Board Fam Med. 2021;34:233–43.
20. Gray N, Calleja D, Wimbush A, Miralles-Dolz E, Gray A, De Angelis M, et al. Is "no test is better than a bad test"? Impact of diagnostic uncertainty in mass testing on the spread of COVID-19. PLoS One. 2020;15:e0240775.
21. Cohen A, Kessel B, Milgroom M. Diagnosing SARS-CoV-2 infection: the danger of over-reliance on positive test results. medRxiv 2020.
22. Mertens P, De Vos N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, et al. Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. Front Med (Lausanne). 2020;7:225.
23. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, et al. Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. Int J Infect Dis. 2020;99:397–402.
24. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan. Jpn J Infect Dis. 2020;73:304–7.
25. Fujimoto K, Chan KH, Takeda K, Lo KF, Leung RH, Okamoto T. Sensitive and specific enzyme-linked immunosorbent assay using chemiluminescence for detection of severe acute respiratory syndrome viral infection. J Clin Microbiol. 2008;46:302–10.
26. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal Swab Specimen. N Engl J Med. 2020;382:e76.
27. Islam KU, Iqbal J. An Update on Molecular Diagnostics for COVID-19. Front Cell Infect Microbiol. 2020;10:560616.
28. Nuccetelli M, Pieri M, Grelli S, Ciotti M, Miano R, andreoni M, et al. SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Cell Death Discov. 2020;6:38.
29. Leuzinger K, Gosert R, Sogaard KK, Naegle K, Bielicki J, Roloff T, et al. Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures. J Med Virol 2020.
30. Bustos P, Tambley C, Acevedo A, Andrade W, Leal G, Vidal D, et al. Quantitative Detection of SARS-CoV-2 RNA in nasopharyngeal samples from infected patients with mild disease. J Med Virol 2020.
31. Service R. One number could help reveal how infectious a COVID-19 patient is. Should test results include it? Science; 2020.
32. Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020;71:793–8.
33. Wolfel R, Cormack VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–9.

Figures
Figure 1

Assay protocol of the HISCL SARS-CoV-2 Antigen assay kit. The biotinylated SARS-CoV-2 Ag antibody (R1) was allowed to react with the sample at 42 °C for 3 minutes. Then, streptavidin-bonded magnetic particles (R2) were added and allowed to react at 42 °C for 2 minutes. After protein separation and washing, ALP-bound SARS-CoV-2 Ag antibody (R3) was added and reacted at 42 °C for 3 minutes. After another magnetic separation and washing, buffer solution (R4) and the chemiluminescent substrate (R5) were allowed to react at 42 °C for 5.5 minutes, then the luminescence intensity was measured. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; ALP: alkaline phosphatase; Ag: antigen.
Figure 2

Western blot analysis. Anti-SARS-CoV antibodies (lane 1 and 2) and anti-His antibodies (lane 3) reacting with SARS-CoV-2 antigens. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; His: histidine.
Figure 3

Standard curve for relations between Ct values and copy numbers. Error bars indicate SD. Ct: cycle threshold; SD: standard deviation.

\[ y = -3.43x + 50.1 \]

\[ r^2 = 0.999 \]
Figure 4

Receiver operating characteristic (ROC) curve analysis.
Figure 5

A scatter plot of HISCL SARS-CoV-2 Antigen (COI) and copy numbers measured by RT-qPCR tests. Data are plotted as logarithmic scales and the plots were fitted with a power approximation.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CriticalCareAdditionalFilesS104232021.docx